The University of Chicago Header Logo

Connection

Wendy Stock to Disease Progression

This is a "connection" page, showing publications Wendy Stock has written about Disease Progression.
Connection Strength

0.148
  1. The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood. 2021 11 11; 138(19):1870-1884.
    View in: PubMed
    Score: 0.036
  2. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.024
  3. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905.
    View in: PubMed
    Score: 0.019
  4. Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012 Sep 06; 120(10):2098-108.
    View in: PubMed
    Score: 0.019
  5. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211.
    View in: PubMed
    Score: 0.016
  6. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006 Feb 21; 103(8):2794-9.
    View in: PubMed
    Score: 0.012
  7. Progressive transformation of germinal centers. Report of 2 cases and review of the literature. Acta Haematol. 2002; 108(1):33-8.
    View in: PubMed
    Score: 0.009
  8. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 1996 Oct 01; 88(7):2665-70.
    View in: PubMed
    Score: 0.006
  9. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996 May; 52(1):42-6.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.